- Silk Road Medical press release ( NASDAQ: SILK ): Q3 GAAP EPS of -$0.29 beats by $0.14 .
- Revenue of $37.4M (+51.4% Y/Y) beats by $3.76M .
- Cash, cash equivalents and short-term investments were $105.1 million as of September 30, 2022.
- Gross profit for the third quarter of 2022 was $28.1 million compared to $18.6 million for the third quarter of 2021. Gross margin was 75% for the third quarter of 2022 and 2021.
-
2022 Financial Guidance- Silk Road Medical now projects revenue for the full year 2022 to range from $134 million to $137 million, vs $130.67M Consensus
For further details see:
Silk Road Medical GAAP EPS of -$0.29 beats by $0.14, revenue of $37.4M beats by $3.76M